BIO Announces Initial Selection of Life Sciences Companies to Present at the 13th Annual BIO CEO & Investor Conference

  • Contact: Erin Reese
  • Phone: 202-962-9235
  • Recommend
  • Tweet
  • Print
  • Email

WASHINGTON, D.C. (Monday, December 13, 2010) - The Biotechnology Industry Organization (BIO) today announced the initial selection of presenting companies for the 13th Annual BIO CEO & Investor Conference, taking place at the Waldorf=Astoria Hotel in New York City on February 14-15, 2011.

“The companies making presentations at this year’s BIO CEO & Investor Conference bring with them a broad range of innovative new therapies in the life sciences sector,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “This is an ideal venue for investors, analysts, and executives alike to get the pulse on the current and proposed investment trends in biotechnology.”

BIO and the conference advisory committee established the criteria for presenting companies. The advisory committee is comprised of members from top-tier firms focused on investing and banking in the life sciences industry in addition to executives from emerging and leading biotech companies. Following are the members of the 13th Annual BIO CEO & Investor Conference Advisory Committee:

  • Hany Awadalla, Managing Director, Rodman & Renshaw, LLC.
  • Ron Cohen, MD President & Chief Executive Officer, Acorda Therapeutics
  • John Crowley, President & Chief Executive Officer, Amicus Therapeutics
  • J. Donald deBethizy, PhD, President & Chief Executive Officer, Targacept, Inc.
  • David Farhadi, MD, Vice President & Portfolio Manager, Fred Alger Management
  • Annette Grimaldi, Managing Director, BMO Capital Markets
  • Rajiv Kaul, Portfolio Manager/Research Analyst, Fidelity Investments
  • Thomas Okarma, President & Chief Executive Officer, Geron Corporation
  • Stephen Sands, Vice Chairman, US Investment Banking; Co-Head of Global Healthcare Group, Lazard
  • Chris Swindle, Managing Director, Wedbush PacGrow Life Sciences
  • Yaron Werber, MD, Director & Senior Biotechnology Analyst, Citi Investment Research

The BIO CEO & Investor Conference will feature presentations from more than 130 emerging and established public biotech companies and non-profit funding organizations.

The following companies will present at the 13th Annual BIO CEO & Investor Conference:

  • Aastrom Biosciences, Inc.: ASTM
  • ACADIA Pharmaceuticals Inc.: ACAD
  • Acorda Therapeutics, Inc.: ACOR
  • Addex Pharmaceuticals: SWF:ADXN
  • Advanced Cell Technology, Inc.: ACTC
  • ADVENTRX Pharmaceuticals, Inc.: AMEX:ANX
  • Aegerion Pharmaceuticals, Inc.: AEGR
  • Aeolus Pharmaceuticals, Inc.: OTC:AOLS
  • Affymax, Inc.: AFFY
  • Agennix AG: ETR:AGX
  • Alimera Sciences, Inc.: ALIM
  • Alkermes, Inc.: ALKS
  • Allon Therapeutics Inc.: TSE:NPC
  • Alnylam Pharmaceuticals, Inc.: ALNY
  • Amsterdam Molecular Therapeutics: AMS:AMT
  • Apricus Biosciences, Inc.: APRI
  • Aradigm Corporation: OTC:ARDM
  • Arena Pharmaceuticals, Inc.: ARNA
  • ARIAD Pharmaceuticals, Inc.: ARIA
  • AVI BioPharma, Inc.: AVII
  • BioDelivery Sciences International: BDSI
  • BioSante Pharmaceuticals, Inc.: BPAX
  • Cadence Pharmaceuticals, Inc.: CADX
  • CEL-SCI Corporation: CVM
  • Cempra Pharmaceuticals: Private  
  • Cerus Corporation: CERS  
  • ChemGenex Pharmaceuticals: ASX:CXS
  • Cleveland BioLabs Inc.: CBLI
  • Clinical Data, Inc.: CLDA
  • CorMedix Inc.: CRMD
  • Curis Inc.: CRIS
  • Cyclacel Pharmaceuticals, Inc.: CYCC
  • Cytokinetics, Inc.: CYTK
  • Cytos Biotechnology AG: SWF:CYTN
  • CytRx Corporation: CYTR
  • Depomed, Inc.: DEPO
  • DURECT Corporation: DRRX
  • Elite Pharmaceuticals, Inc.: OTC:ELTP
  • EpiCept Corporation: EPCT
  • Exelixis, Inc.: EXEL
  • Furiex Pharmaceuticals, Inc.: FURX
  • Genta Incorporated: OTC:GETA
  • GenVec, Inc.: GNVC
  • Geron Corporation: GERN
  • GlobeImmune Inc.: Private  
  • Hybrigenics S.A.: EPA:ALHYG
  • Icagen, Inc.: ICGN
  • Idenix Pharmaceuticals, Inc.: IDIX
  • Idera Pharmaceuticals, Inc.: IDRA
  • ImmunoGen, Inc.: IMGN
  • Immunovaccine Inc.: CVE:IMV
  • Inovio Pharmaceuticals, Inc.: AMEX:INO
  • Karo Bio AB: STO:KARO
  • Keryx Biopharmaceuticals, Inc.: KERX
  • Lexicon Pharmaceuticals, Inc.: LXRX
  • Ligand Pharmaceuticals, Inc.: LGND
  • Medicago Inc.: CVE:MDG
  • MethylGene Inc.: TSE:MYG
  • Momenta Pharmaceuticals, Inc.: MNTA
  • Myriad Genetics, Inc.: MYGN
  • Neoprobe Corporation: OTC:NEOP
  • NeurogesX, Inc.; NGSX
  • Novavax, Inc.: NVAX
  • Oncolytics Biotech Inc.: TSE:ONC
  • Oncothyreon Inc.: ONTY
  • Opexa Therapeutics, Inc.: OPXA
  • OXiGENE, Inc.: OXGN
  • PDL BioPharma, Inc.: PDLI
  • Peregrine Pharmaceuticals, Inc.: PPHM
  • PolyMedix Inc.: OTC:PYMX
  • Pro-Pharmaceuticals, Inc.: PRWP
  • PTC Therapeutics, Inc.: Private 
  • QRxPharma Limited: ASX:QRX 
  • RegeneRx Biopharmaceuticals, Inc.: RGN
  • Repligen Corporation: RGEN
  • Resverlogix Corp.: TSE:RVX
  • Rigel Pharmaceuticals, Inc.: RIGL
  • Sangamo BioSciences, Inc.: SGMO
  • Santarus, Inc.: SNTS
  • SciClone Pharmaceuticals, Inc.: SCLN
  • SIGA Technologies, Inc.: SIGA
  • Soligenix, Inc.: OTC:SNGX
  • Somaxon Pharmaceuticals: SOMX
  • Spectrum Pharmaceuticals, Inc.: SPPI
  • Sunesis Pharmaceuticals, Inc.: SNSS
  • SuperGen, Inc.: SUPG  
  • Synergy Pharmaceuticals, Inc.: OTC:SGYP  
  • Synta Pharmaceuticals Corp.: SNTA
  • Targacept, Inc.: TRGT
  • Tekmira Pharmaceuticals Corporation: TSE:TKM
  • Telik, Inc.: TELK
  • Tengion, Inc.: TNGN
  • Topotarget A/S: CPH:TOPO
  • Transcept Pharmaceuticals, Inc.: TSPT
  • Unigene Laboratories, Inc.: OTC:UGNE
  • VirtualScopics: VSCP
  • XOMA LLC: XOMA
  • YM BioSciences Inc.: TSE:YM
  • Zalicus Inc.: ZLCS
  • ZIOPHARM Oncology, Inc.: ZIOP

The program will also include therapeutic workshops featuring CSOs, MDs and industry analysts discussing new therapies and the latest areas of pipeline innovation in rheumatology, hepatology, endocrinology, neurology, and oncology.

Business Roundtables will focus on current investment trends and topics in biotechnology including financing, business development, licensing, M&A, clinical trial success rates, and reimbursement strategies.  In addition, plenary session topics will highlight investor perceptions of the industry and the health policy outlook for 2011.

Attendees will have the opportunity to network with leading industry executives and investors, as well as utilize the BIO One-on-One Partnering system to set up investment meetings with new and existing contacts.

Additional presenting companies are confirmed each day. For the most up-to-date list, please visit http://bio.org/bioceo. Registration is complimentary for qualified investors and members of the media.

About the 13th Annual BIO CEO & Investor Conference

The BIO CEO & Investor Conference is a must attend event for institutional investors, industry analysts, and senior biotechnology executives focused on shaping the future investment landscape of the biotechnology industry.

BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors, including Lead Bank Sponsor Wedbush PacGrow Life Sciences, Host Bank Sponsor Rodman & Renshaw LLC, and Supporting Bank Sponsors BMO Capital Markets, Deutsche Bank, and Lazard.

 

Upcoming BIO Events

Pacific Rim Summit on Industrial Biotechnology and Bioenergy
December 11-14, 2010
Honolulu, HI

BIO Asia International Partnering Conference
January 24-25, 2011
Tokyo, Japan

BIO CEO & Investor Conference
February 14-15, 2011
New York, NY

BIO-Europe Spring 2011
March 14-16, 2011
Milan, Italy

BIO Intellectual Property Counsels Committee Spring Conference and Committee Meeting
April 13-15, 2011
Seattle, WA

BIO International Convention
June 27-30, 2011
Washington, DC

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech Now, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtech Now.

For more information:

  • Visit http://www.bio.org
  • Follow us on Twitter @IAmBiotech
  • Join us on LinkedIn/MyBio
  • Become a fan at facebook.com/IAmBiotech

###

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.